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METHODS & TECHNIQUES
Reprogrammable CRISPR/Cas9-based system for inducing site-
specific DNA methylation
James I. McDonald1,*, Hamza Celik2,*, Lisa E. Rois1, Gregory Fishberger3, Tolison Fowler1, Ryan Rees3,
Ashley Kramer2, Andrew Martens2, John R. Edwards1,‡ and Grant A. Challen2,4,‡
ABSTRACT
Advances in sequencing technology allow researchers tomap genome-
wide changes in DNA methylation in development and disease.
However, there is a lack of experimental tools to site-specifically
manipulate DNA methylation to discern the functional consequences.
We developed a CRISPR/Cas9 DNA methyltransferase 3A (DNMT3A)
fusion to induce DNA methylation at specific loci in the genome. We
induced DNA methylation at up to 50% of alleles for targeted CpG
dinucleotides. DNA methylation levels peaked within 50 bp of the short
guide RNA (sgRNA) binding site and between pairs of sgRNAs. We
used our approach to target methylation across the entire CpG island at
the CDKN2A promoter, three CpG dinucleotides at the ARF promoter,
and the CpG island within theCdkn1a promoter to decrease expression
of the target gene. These tools permit mechanistic studies of DNA
methylation and its role in guiding molecular processes that determine
cellular fate.
KEY WORDS: CRISPR/Cas9-based system, CpG dinucleotides,
DNA methylation
INTRODUCTION
DNA methylation of CpG dinucleotides is a prominent epigenetic
modification of the mammalian genome that can influence gene
expression, and aberrant distribution of DNA methylation is
associated with a spectrum of human disorders including cancers
(Egger et al., 2004). Despite intensive study, it remains unclear
which CpG dinucleotides must change methylation state in order to
alter transcription. Genome-wide analyses have found associations
between DNA methylation and reduced gene expression that occur
both in the proximal promoter and downstream of the gene’s
transcription start site (TSS) (Bell et al., 2011; Bock et al., 2012;
Lou et al., 2014; VanderKraats et al., 2013; Lund et al., 2014).
However, evidence supports both that DNAmethylation can cause a
loss of expression, and that expression changes can alter DNA
methylation patterns (Bestor et al., 2015; Busslinger et al., 1983).
Here, we sought to develop tools for locus-specific epigenetic
remodeling to directly address the role of DNA methylation in
regulating gene expression.
Targeted DNA methylation approaches have been attempted by
fusing DNA methyltransferase enzymes (DNMTs) to DNA-
binding proteins such as zinc finger proteins (ZFPs) (Siddique
et al., 2013), and transcriptional activator-like effector (TALE)
(Bernstein et al., 2015). However, engineering custom proteins for
each targeted sequence is laborious and requires specialized
expertise. Moreover, in these studies, induced DNA methylation of
the targeted loci was relatively poor, with substantial off-target
activity. An engineered form of the clustered, regularly
interspaced, short palindromic repeat (CRISPR) system has
emerged as an alternative for achieving site-specific DNA
targeting (Jinek et al., 2012). Here, the Cas9 endonuclease is
directed to genomic targets by engineered short guide RNAs
(sgRNAs) (Jinek et al., 2012). Because the sgRNA is the DNA
sequence-specific component of the system, it allows for efficient
targeting of multiple regions due to the ease of design and
synthesis of new sgRNAs (relative to engineering new custom
proteins for each target site). A Cas9 mutant (D10A and H840A;
henceforth referred to as dCas9) that lacks endonuclease activity
but can still be recruited by sgRNA(s) (Jinek et al., 2012) has
recently been used to target genes in mammalian cells for
transcriptional activation (Perez-Pinera et al., 2013a,b; Maeder
et al., 2013; Mali et al., 2013). Here, we demonstrate an easily
reprogrammable CRISPR/dCas9 DNMT fusion capable of
inducing site-specific DNA methylation.
RESULTS
To design a flexible system to target DNA methylation, we fused
dCas9 to the catalytic domain of the de novo DNA
methyltransferase DNMT3A (Fig. 1A). To test this system we
targeted DNA methylation to the tumor suppressor gene CDKN2A
(cyclin dependent kinase 2A), which inhibits progression through
the cell cycle (Liggett and Sidransky, 1998). CDKN2A is one of the
most frequently hypermethylated genes in The Cancer Genome
Atlas (Ciriello et al., 2013), and numerous clinical studies show a
negative correlation between CDKN2A methylation and expression
in colorectal cancer (Shima et al., 2011). While it is generally
assumed that CDKN2A methylation induces gene silencing, it has
also been suggested that DNA methylation occurs after the loss of
expression (Hinshelwood et al., 2009). From a literature search, we
identified 17 publications that associate CDKN2A methylation with
expression and/or cancer (Fig. S1.1). Overwhelmingly, these papers
studied the differentially methylated region (cancer DMR, cDMR)
on the 3′ end of the CpG island that overlapped the first exon of
CDKN2A (Fig. 1B).Received 14 April 2016; Accepted 18 April 2016
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We computationally designed three sgRNAs (g1a, g7a and g33a)
to target this region and test whether DNA methylation was
sufficient to induce gene silencing. We validated the ability of each
sgRNA to target the CDKN2A locus by transfecting them with
active CRISPR/Cas9 and measuring the ability of Cas9 to cleave the
locus (Fig. S1.2, Table S1). We then transfected HEK293T cells
with the pool of three sgRNAs along with either a normal dCas9-
DNMT3A catalytic domain (CD) fusion (dCas9-D3A) or onewith a
DNMT3AE756A mutation (dCas9-mD3A, Fig. 1A), which abolishes
DNA methyltransferase activity (Reither et al., 2003). Transfection
efficiencies were >80-90% for all experiments as measured by co-
transfection with GFP-containing plasmids. We analyzed DNA
methylation levels for 20 days post-transfection using Illumina
sequencing of two amplicon regions (amplicon bisulfite
sequencing, ABS). ABS results were validated using Sanger
bisulfite sequencing (R2=0.83; Fig. S1.3), and DNA methylation
levels at CpGs analyzed in both of two independent ABS
amplicons showed strong correspondence (R2=0.98; Fig. 1C). All
CpGs had >100× sequencing coverage, with a median coverage of
15,200.
Over the 20-day time course we observed an increase in DNA
methylation at theCDKN2A target locus that ranged from 20-43% at
its peak on day three. Background methylation from transfection
with dCas9-mD3a was consistently less than 1.5%, while
background methylation from an off-target sgRNA, which
controls for DNMT3A-CD overexpression, was less than 14% on
day three. Induced DNA methylation levels were highest over a set
of eight CpGs directly between the g33a and g7a sgRNA target sites
(Fig. 1C). Increases in CHG and CHH methylation were minimal
(Fig. S1.4). DNA methylation decreased rapidly after passaging the
cells on day four, but stabilized 20 days post-transfection at 6-10%
(Fig. 1D; Fig. S1.5). Despite the literature support for a negative
Fig. 1. Site-specific induction of DNA methylation using a CRISPR-Cas9 DNMT fusion. (A) dCas9-DNMT3A CD fusion constructs. The E756A mutation
inactivates the DNMT3A-CD. NLS, nuclear localization signal; FLAG, FLAG tag domain. (B) UCSC genome browser view showing the locations of the three
CDKN2A sgRNA (g1a, g7a and g33a). The three sgRNA were validated to ensure they targeted this locus (Fig. S1.2). cDMR indicates the region from the
literaturewheremethylation changes are associated with expression changes (Fig. S1.1). (C) Induced DNAmethylation at theCDKN2A promoter three days post-
transfection. Colors correspond to the red and blue ABS regions in B. Three CpGs were independently measured in both amplicons. sgRNA target sites are
indicated above the graphs. Pool sgRNA indicates g1a, g7a, g33a were used simultaneously. Sanger sequencing validation is presented in Fig. S1.3, and non-
CpG methylation data is presented in Fig. S1.4. (D) Time course of the percent methylation data for the CpG marked with an asterisk in C. Additional CpGs are
shown in Fig. S1.5. (E) Methylation induced by a pair of sgRNA decreases with increasing intervening distance. Distance is calculated relative to the 3′ end of the
g33a sgRNA. Diamonds indicate the location each CpGmonitored for methylation; whose color corresponds to appropriate line in the graph. Additional data from
individual and paired sgRNA is presented in Fig. S1.6. (F) CDKN2A expression for samples with induced methylation. Expression is normalized to day one for
each respective sample. Error bars=mean±s.e.m. (n=1 performed in technical triplicate).
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correlation between expression and DNAmethylation in this region,
we did not observe a measurable effect on CDKN2A gene
expression by RT-qPCR (Fig. 1F). This suggests that a limited
increase in methylation in the region 100-400 bp downstream of the
CDKN2A TSS is insufficient to trigger gene silencing.
Spatially, the induced DNA methylation spiked near the sgRNA
target sites and dropped quickly toward background levels at
surrounding CpG sites. Analysis of DNA methylation induced by
single sgRNAs indicates that methylation occurs primarily within
50 bp of the sgRNA binding site (Fig. S1.6). Higher DNA
methylation levels were often observed 3′ of the sgRNA binding
site (Fig. S1.6). Our initial data from the three pooled sgRNAs
suggested that CpG methylation was higher between pairs of
sgRNAs. To investigate this effect, we transfected pairs of sgRNA
with varying intervening distances and monitored methylation of
six clustered CpGs between the sgRNA pairs using ABS (Fig. 1E).
DNA methylation of the three CpGs (cluster 1) within 20 bp of the
fixed sgRNA (g33a) did not change with addition of a second
sgRNA 77 bp or further away. However, the methylation level
increased from 30-40% to 42-53% when sgRNAs were paired
within 80 bp and both sgRNAs were within 50 bp of CpG cluster 2
(Fig. 1E). This suggests the DNMT3A-CD activity at the target
locus is additive.
We next tested whether we could use our approach to methylate
an entire CpG-island (CGI). We designed 17 sgRNAs (Fig. 2A;
Table S1) to target DNA methylation across the CDKN2A CGI,
which spans the TSS. We applied three combinations of sgRNAs
(Set 1, 2, All) to test whether inducing DNA methylation of the
entire CGI could decrease gene expression (Fig. 2A). ABS analysis
of eight amplicons (minimum per CpG sequencing depth of 100)
showed that the DNA methylation level increased to an average of
22% across the entire region with a peak of 54% (Fig. 2B). As an
off-target negative control, we used three sgRNAs targeted to the
ARF promoter located ∼20 kb away. The average background
methylation at CDKN2A after treatment with off-target ARF
sgRNAs was 9% (Fig. 2B). The other two sgRNA sets (Set 2 and
All) induced similar increases of methylation across the CGI
overlapping the TSS of CDKN2A (Fig. S2).
Analysis of CDKN2A expression by RT-qPCR in all three
sgRNA targeting experiments (Set 1, 2, All) indicated an average
39% decrease in CDKN2A mRNA expression after targeting with
dCas9-D3A (Fig. 2C). Cells transfected with dCas9-mD3A showed
a 16-26% reduction in CDKN2A expression, likely due to CRISPR
inhibition (Fig. 2C). Across the three replicates (Set 1, 2, All)
expression decreased by an average of 17% in dCas9-D3A relative
to dCas9-mD3A (P<0.01 paired-t-test). This indicated that DNA
Fig. 2. DNA methylation decreases
gene expression at the CDKN2A
promoter in a context dependent
manner. (A) Locations of the 17
sgRNAs used in Sets 1 and 2 and
regions sequenced in B. sgRNA
coordinates are in Table S1. (B)
Percent methylation is plotted for
regions designated in A. Set 1 sgRNA
target sites are indicated above the
graphs. Data for All sgRNA, Set 2
sgRNA, and off-target SgRNA is
presented in Fig. S2. (C) Methylation
induced by CDKN2A-targeted sgRNA
Set 1, Set 2, and All sgRNA,
decreases gene expression. Relative
expression of CDKN2A is normalized
to a mock-treated control. Error
bars=mean±s.e.m. (All, n=2; Set 1,
n=1; Set 2, n=1; all performed in
technical triplicate, paired t-test).
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methylation directly decreased CDKN2A expression, but targeting
of the entire CGI was required to trigger this effect. Our results are
consistent with other studies that find a similar reduction in gene
expression after inducing methylation at the CDKN2A promoter
using ZFP- and TALE-based systems (Bernstein et al., 2015; Cui
et al., 2015).
To verify the effect of our system with a separate locus, we
designed three inwardly-directed (5′ to 3′) sgRNAs that bracketed
three CpG sites in the ARF promoter located 150-170 bp
downstream of the TSS (Fig. 3A). ARF-targeted sgRNAs
increased the DNA methylation level to 27-30% at these three
CpG sites with less than 15% methylation induced in adjacent sites
(Fig. 3B). Induced methylation of the ARF promoter was associated
with a 19% decrease in its expression (Fig. 3C).
To further validate our design rules, we attempted to induce
DNA methylation in a different system in a regulated fashion
with a minimalistic combination of sgRNAs. dCas9-D3A
and dCas9-mD3A were cloned into a doxycycline-inducible
lentivirus where expression of the fusion protein is linked to
mCherry via internal ribosome entry site (IRES), and targeted to
the Cdkn1a locus with two rationally-designed sgRNAs. We
designed two sgRNAs targeting the CpG island located in the
Cdkn1a promoter (Fig. 4A) and cloned them into lentiviral
vectors (in which sgRNAs and GFP are expressed constitutively
from two different promoters) (Fig. S4.1) and transduced 32D
cells (mouse IL3-dependent myeloid progenitor cell line with an
unmethylated Cdkn1a promoter and active Cdkn1a expression).
Additional negative controls were generated by transducing 32D
cells with sgRNAs only, dCas9-D3A only, or sgRNAs plus
dCas9-mD3A. Cells were then FACS-sorted by GFP and/or
mCherry to establish stable cell lines. Analysis of the stable cell
lines induced by doxycycline showed successful expression of
dCas9-fusions and sgRNAs via mCherry and GFP signal
(Fig. S4.2). In the absence of doxycycline, the expression of
fusion constructs was silenced (Fig. S4.2).
Stable cells were induced with doxycycline for eight days.
Cdkn1a promoter DNA methylation and gene expression were then
evaluated by bisulfite sequencing and RT-qPCR respectively. Cells
transduced with dCas9-D3A together with sgRNAs showed an
increase in Cdkn1a promoter DNA methylation by over 25% across
the entire target region (and by as much as 40-85% at individual
CpGs around sgRNAs) compared to all control groups (Fig. 4B,C),
and a reduction in Cdkn1a expression by approximately 40%
(Fig. 4D). There was no difference in Cdkn1a promoter DNA
methylation or expression between any control groups (Fig. 4B-D).
Cells transduced with dCas9-D3A together with sgRNAs showed a
growth advantage, consistent with an increase in proliferation due to
repression of a cell cycle inhibitor (Fig. 4E). As with targeting of the
human CDKN2A locus, these data suggested that induced DNA
methylation pioneered by dCas9-D3A targeted with a minimal
combination of sgRNAs can influence gene expression and generate
subsequent downstream functional phenotypes.
We reverse cloned viral integrants to identify clones that
contained either one of the two guides, or both sgRNAs together
with dCas9-D3A. No induced promoter DNA methylation or
reduction in gene expression was observed in clones expressing
only a single sgRNA (Fig. 5A,B). In contrast, Cdkn1a promoter
methylation was increased and its expression decreased in clones
that expressed both sgRNAs (Fig. 5A,B). To confirm the presence
of both sgRNAs were required to execute induced DNA
methylation, clones that contained only a single sgRNA were
transduced with their complementary sgRNA. Following this, after
eight-days of induction, Cdkn1aDNAmethylation increased across
the promoter by up to 33% compared to the parental clone that
contained only a single sgRNA (Fig. 5C). Cdkn1a expression was
reduced by 40-50% in the complemented clones (Fig. 5D). These
Fig. 3. Induced methylation decreases ARF
expression. (A) Locations of the three sgRNA used
to induce DNA methylation at the ARF promoter.
(B) Percent methylation is plotted for a region of
exon 1 of the ARF locus. ARF sgRNA target sites
and three targeted CpGs (asterisks) are indicated
above. (C) Methylation induced by ARF targeted
sgRNA decreases gene expression. Relative
expression of ARF is normalized to a mock-treated
control. Error bars=mean±s.e.m. (n=1 biological
replicate performed in technical triplicate).
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data indicate that targeting with multiple sgRNAs results in a
synergism and induces robust DNAmethylation. We also examined
the stability of the induced DNA methylation by withdrawing
doxycycline for eight days.Cdkn1a promoter DNAmethylation and
expression profiles remained largely unchanged (Fig. 5E,F) even
though expression of dCas9-D3A was silenced (Fig. S4.2).
To assess non-specific activity in this system, we initially
attempted to analyze off-target genomic areas with high homology
to predicted binding regions of both Cdkn1a sgRNAs. However, no
regions with high homology were found as these sgRNAs were
designed based on their minimal off-target binding and the presence
of a PAM-site. As an alternative, we measured the global DNA
methylation levels between cells that contained fusion proteins
(dCas9-D3A or dCas9-mD3A) in the presence of both sgRNAs
(Fig. 6A), as well as the local DNA methylation profile of CpG
islands located upstream and downstream of theCdkn1a target locus
(Srsf3 and off-target Cdkn1a respectively), and the promoter CpG
islands of the related cell cycle family members Cdkn1b and
Cdkn2d (Fig. S6). Srsf3 and off-target Cdkn1a are adjacent to
Cdkn1a target locus on chromosome 17 (chr17), whereas Cdkn1b
(chr6) and Cdkn2d (chr4) are distant loci. We found no statistically
significant difference in global 5-methylcytosine (5-mC) levels
between different groups or across the regions that were analyzed
(Fig. 6A,B).
DISCUSSION
We provide an outline for using a modified CRISPR/dCas9 system
to evaluate the functional relevance of DNA methylation at specific
CpGs and described guidelines for its use. DNA methylation
induction occurs within ∼50 bp of a sgRNA target site and is
strongest between two adjacent and inwardly directed sgRNA
binding sites. Based on our design criteria, we designed sets of
sgRNAs that induced methylation at the human CDKN2A and ARF
promoters, and the mouse Cdkn1a promoters with similar
efficiency. Induced methylation was sufficient to decrease
expression of all three genes. Methylation increases and changes
in expression were highly significant and reproducible either by
usingmultiple distinct sgRNA combinations in the case ofCDKN2A
or at the clonal levels as observed for Cdkn1a. Moreover, the
reduction in Cdkn1a expression clearly had functional
consequences (increased proliferation) for the transduced cells.
Though modest, the expression decreases caused by induced
methylation are consistent with previously published results using
ZFP and TALE fusions (Bernstein et al., 2015; Cui et al., 2015).
The effects of the induced methylation also appeared to be
context dependent. While methylation of the entire CGI at the
CDKN2A promoter repressed gene expression, inducing DNA
methylation of a region 100-400 bp downstream of the CDKN2A
TSS alone was insufficient to affect expression despite the frequent
observation of a negative correlation between methylation and
expression in this region. This indicates the importance of the
flexibility to target multiple regions offered by our CRISPR/dCas9
DNMT fusion system.
Although approaches for targeted DNA methylation have been
previously described, our method is advantageous for several reasons
including; (1) the ease of designing new sgRNAs for targeting, (2)
Fig. 4. Targeted CpG methylation of the Cdkn1a
locus using dCas9-D3A fusion protein.
(A) Organization of the mouse Cdkn1a target locus
with CpG islands indicated with green boxes. Blue
arrow indicates the location of transcriptional start site
(TSS). Red arrows indicate the relative position of
sgRNA binding sites (5′ to 3′) within the 5′ CpG island.
Black arrows indicate the relative positions of CpGs.
(B) Bisulfite sequencing analysis of Cdkn1a promoter
in 32D cells transduced with sgRNAs or dCas9-D3A
only, and dCas9a-D3A or dCas9-mD3Awith sgRNAs.
Changes in methylation of specific CpGs are indicated
by pie charts. Shading indicates the average amount
of DNA methylation at each CpG (n=14-15 biological
replicates representative of three independent
experiments). (C) Average DNA methylation level of
target locus within Cdkn1a promoter (unpaired t-test).
(D) mRNA expression level of Cdkn1a (normalized to
18S) in transduced 32D cells (n=2 biological replicates
performed in technical duplicate; unpaired t-test).
(E) Growth kinetics of transduced 32D cells (n=2
biological replicates performed in technical
quadruplicate; unpaired t-test). *P<0.05,
****P<0.0001, error bars=mean±s.e.m.
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higher levels of induced DNA methylation, (3) little off-target
activity. This approach can be used to interrogate the effects of DNA
methylation on only a few CpG sites by bracketing them with
sgRNAs, or can be used to test the effects of broader increases inDNA
methylation by using many sgRNAs simultaneously. Further, the
method described here provides a robust, reprogrammable approach
to allow researchers to easily and thoroughly explore the functional
roles of DNA methylation changes in development and disease.
MATERIALS AND METHODS
dCas9 fusion protein design and construction
The catalytic domain (CD) of human DNMT3A (amino acids 598 to 912 of
NP_783328.1) both with and without the E756A mutation was cloned
between the NheI and AgeI sites of pCMV_dCas9_VP64 (Addgene plasmid
#49015, Cambridge, MA) with a NLS and FLAG tag linker. For lentivirus
plasmids, TetO-FUW-OSKM (Addgene plasmid #20321), was digested with
EcoRI and a multiple cloning site containing EcoRI, XbaI, NheI, AgeI,
PspXI, AscI and EcoRI was cloned into this plasmid to generate TetO-FUW
plasmid. An IRES-mCherry insert was amplified by PCR and cloned into
AgeI- andAscI-digested TetO-FUW to generate TetO-FUW-IRES-mCherry.
dCas9-D3A or dCas9-mD3A was cloned into this plasmid using XbaI and
AgeI sites to generate TetO-dCas9-D3A or TetO-dCas9-mD3A. In the final
plasmid, expression of both fusion proteins is controlled from the tetracycline
operator (tetOP) and aminimal CMVpromoter. The full amino acid sequence
of the dCas9-3a or dCas9-3aΔ protein is shown in Fig. S4.1. Plasmids
sequences were validated by Sanger sequencing and prepared for transfection
using a Qiagen Maxiprep kit. All plasmids are available in Addgene, and
detailed protocol information is available at http://epigenomics.wustl.edu/
epigenomeEditing and http://www.challenlab.com.
sgRNA design
Target sequences were entered into the MIT sgRNA design software
(http://crispr.mit.edu/), the BROAD sgRNA design tool (http://www.
broadinstitute.org/rnai/public/analysis-tools/sgrna-design-v1) (Doench et al.,
2014), and the sgRNAcas9 tool (version 2.0.10) (Xie et al., 2014). The
intersection of sgRNA target sites produced by all tools was taken for further
analysis. sgRNA sequences that failed the BROAD test (score<0.2) were
excluded. sgRNAwere selected based on high BROAD scores and location
relative to other sgRNAs. sgRNA coordinates and sequences are in
Tables S1 and S2. Oligonucleotides corresponding to the target sites were
annealed and cloned into MLM3636 (Addgene plasmid #43860). For
lentivirus plasmids, U6-sgRNA coding sequences were amplified from
pMLM3636 by PCR and cloned into an EcoRI and ClaI linearized
pLVTHM lentiviral backbone (Addgene plasmid #12247) generating pL-
sgRNA1 and pL-sgRNA2 in which GFP is expressed from EF1a promoter.
Cell culture, lentiviral production and doxycycline induction
HEK293T cells were acquired from ATCC (CRL-3216, Manassas, VA) and
grown in DMEM supplemented with 10% FBS (Gibco, Waltham, MA), 1×
Penicillin/Streptomycin (Gibco), and 2 mM GlutaMax (Gibco). For
transfection experiments, 3×105 HEK293T cells were plated in a 60 mm
dish. The next day, the cells were transfected with Lipofectamine LTX
(Thermo Fisher Scientific, Waltham, MA). The Lipofectamine:DNA ratio
was 3.5, with a total of 5.5 μg of plasmid DNA. Themass of Cas9-DNMT3A-
CD fusion plasmid was equal to the total mass of the sgRNA plasmids. Since
HEK293T cells incorporate either all plasmids or none, 0.5 or 0.7 μg of
pMaxGFP was co-transfected in order to indicate the transfection efficiency.
The plasmid DNAwas first diluted in Gibco OptiMEM, then Lipofectamine
LTX was added and mixed in by inversion. After 30 min, the transfection
mixture was added dropwise to the cells and they were placed back in the
incubator. 32D cells (ATCC) cells were maintained in RPMI supplemented
with 10% FBS and 1% penicillin-streptomycin along with 5 ng/ml mouse
interleukin-3 (IL-3). For lentiviral production, 293T cells were co-transfected
with the packaging plasmids pMD2.G and psPAX2 along with the respective
lentiviral plasmid (TetO- dCas9-3a, TetO-dCas9-3aΔ, pL-sgRNA1 and pL-
sgRNA2). Viral supernatant was concentrated by centrifugation at 76,000 g
for 1.5 h at 4°C. Cells were co-transduced with lentiviruses for the target gene
expression along with an rtTA lentivirus (Addgene plasmid #20342) which is
necessary for the activation of doxycycline controlled promoter in vectors
containing the target gene. For transductions, a total of 1×105 32D cells were
plated into 12-well plateswithDMEMcontaining 10% fetal bovine serum and
1× penicillin/streptomycin in the presence IL-3, spin-infected with lentivirus
at MOI of 1:1 at 250 g for 2 h. 24 h post-transduction, cells were washed and
re-plated in fresh media for expansion. For the induction of fusion proteins in
transduced 32D cells, 0.25 µg/ml doxycycline (Sigma, D9891-100G)
was added to the growth media. Every other day, a half-media change with
(0.5 µg/ml) doxycycline was performed.
Sanger bisulfite sequencing
Genomic DNA (gDNA) was isolated using the PureLink Gemonic DNA
Mini Kit (Invitrogen) or the Zymo Research (Irvine, CA) Quick gDNA
Fig. 5. Multiple sgRNAs are required for the efficient establishment of
targetedmethylation. (A) AverageDNAmethylation level of target locuswithin
Cdkn1a promoter (n=12-15 biological replicates representative of two
independent experiments; unpaired t-test). Presence or absence of each
sgRNA in each clone is shown (−; +) at the bottom of the graph. (B) Expression
level of Cdkn1a mRNA in 32D cells transduced with sgRNAs, dCas9-D3A,
dCas9-mD3Awith sgRNAs or dCas9-D3Awith either one or both sgRNAs (n=2
biological replicates performed in technical duplicate; unpaired t-test).
Presence orabsence of each sgRNA in each clone is shown (−; +). (C) Average
promoter DNAmethylation (n=12-15 biological replicates representative of two
independent experiments) or (D) expression level ofCdkn1a in 32Dcells in 32D
cells with one sgRNA which were then transduced with their complementary
sgRNA (n=2 biological replicates performed in technical duplicate; unpaired
t-test). (E) AverageDNAmethylation ofCdkn1a target locus for clones following
doxycycline withdrawal for eight days. Clones were previously induced for
12 days, with starting induced DNA methylation level shown by red error bars
(n=12-16 biological replicates representative of two independent experiments).
(F) Expression level of Cdkn1a in clones after eight days of de-induction (n=2
biological replicates performed in technical duplicate; unpaired t-test). *P<0.05;
**P<0.01; ****P<0.0001, error bars=mean±s.e.m.
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MiniPrep kit and quantified with the Qubit dsDNA broad range assay
(Thermo Fisher Scientific, Waltham, MA). gDNA was bisulfite converted
with the ZymoResearch EZDNAmethylation kit or the Epitech Bisulfite Kit
(Qiagen) according to the manufacturer’s instructions. All samples underwent
bisulfite conversion with a high efficiency of at least 98% as determined by
conversion of unmethylated, non-CpG cytosines. For CDKN2A, the target
regions were amplified with the Qiagen PyroMark PCR kit and CDKN2A_B
primers in Table S3. PCR products were cloned into the Promega pGEM-T
Easy plasmid and transformed into NEB 10β competent cells. PCR products
from individual colonies were sequenced by Sanger.
A nested PCR strategy was used to amplify Cdkn1a target genomic DNA
site. In primary PCR reaction, 20 ng of total bisulfite converted DNA was
used as a template with the primer pair F1 (GTTTAGATTTTTAGAGG
GGAGGG) and R1 (CAAAAACTAAAAAAATAACTACCATCC). PCR
was performed using Taq DNA polymerase (Invitrogen) using following
cycling conditions; (1) 94°C for 3 min, (2) 95°C for 45 s, (3) 58°C for 58°C,
(4) 72°C for 45 s and (5) 72°C for 10 min. Steps 2-4 were repeated for 40
cycles. For the second part of the nested PCR, 1.0 µl of the primary PCR
reaction was used as a template and the same PCR conditions were used with
primer pairs F1 and R2 (TCCTAAAATTCAAACTCTATATACC). The
PCR amplicons were then gel extracted and cloned into pCR4-TOPO TA
vector (Invitrogen) and resulting plasmids were transformed into TOP10
cells (Invitrogen). The target region was PCR amplified from different
clones and the PCR products were sequenced by the Beckman Coulter
Genomics (Danvers, MA, USA). Sanger bisulfite sequencing analysis was
performed using BIQ Analyzer (Bock et al., 2005).
Amplicon bisulfite sequencing
gDNA was extracted, bisulfite converted and PCR amplified as above. A
tenfold molar excess of Illumina sequencing Y-adapters was then annealed
to 100 ng of PyroMark PCR product (total Y-adapter mass varies with PCR
product length) with NEB Quick Ligase for 15 min. The ligations were
purified over a 1.5% agarose II (ISC BioExpress, Kaysville, UT) gel in 1×
TBE in order to remove incompletely ligated DNA. Custom 13 bp barcode
index sequences were added via PCR using NEB Phusion (NEB, Ipswich,
MA). The standard Phusion PCR protocol was followed but with the
following primer concentrations (for a 50 μl reaction): 1 μl of Illumina
Primer 1.0 (25 μM), 1 μl of Illumina PCR Primer 2.0 (0.5 μM), and 1 μl
of the index primer (25 μM). The thermocycler protocol was the following:
(1) 98°C, 30 s; (2) 98°C, 10 s; (3) 64°C, 30 s; (4) 72°C, 30 s; (5) Return to
step two 11 times; (6) 72°C 5 min; (7) 4°C hold. The PCR products were
again purified over a 1.5% agarose II gel in 1× TBE, and their concentration
was measured with the Qubit dsDNA high sensitivity kit. Individually
indexed samples were pooled and submitted for sequencing.
Amplicon bisulfite sequencing data were checked for quality using
fastQC, adaptor and poor quality sequence (quality less than 20) was
trimmed using fqtrim, and the trimmed sequences were mapped to the target
sequences using Bismark (Krueger and Andrews, 2011).
ELISA methylation analysis
For quantification of total 5-mC level, the ELISA-based MethylFlash
Methylated DNA Quantification Kit (Colorimetric; all from Epigentek,
distributed by BioCat GmbH, Heidelberg, Germany) were utilized to
quantify the amount of 5-mC in the DNA of transduced 32D cell lines.
Quantification was performed in technical and biological duplicates
according to the manufacturer’s instructions. 100 ng of total DNA isolated
from each transfected cells was used for 5-mC quantification. For absolute
5-mC quantifications, a standard curvewas generated by plotting the various
concentrations of the positive control provided with the kit against the
optical density (OD) at 450 nm.
Expression analysis
For human cells, RNA was extracted with the Zymo Research Quick
mRNA Miniprep kit. RNA concentration was measured with the Qubit
Fig. 6. Limited off-target activity in dCas9-D3A driven
targeted DNA methylation system. (A) Global 5-mC content
levels in cells transduced with only dCas9-D3A, dCas9-D3A
with sgRNAs, or dCas9-mD3A with sgRNAs targeting Cdkn1a
locus (n=2 biological replicates performed in technical duplicate;
unpaired t-test). (B) Bisulfite sequencing analysis of off-target
CpG islands located upstream or downstream of Cdkn1a target
locus (Srsf3 and off-target Cdkn1a, respectively) or distant loci
(Cdkn1b and Cdkn2d) in cells that are transduced with dCas9-
3a or dCas9-3a with both sgRNAs (n=10-24). Source data in
Table S5. Error bars=mean±s.e.m.
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RNA BR kit. RNA integrity was determined by visualizing rRNA bands
using agarose gel electrophoresis. Reverse transcription was performed
using the Bio-Rad iScript Reverse Transcriptase kit. Quantitative reverse-
transcription polymerase chain reaction (RT-qPCR) was performed with
the Bio-Rad iTaq Universal with SYBR Green reagent on an Applied
Biosystems Viia7 instrument. The thermocycler protocol was the
following: (1) 95°C, 20 s; (2) 95°C, 3 s; (3) 60°C, 20 s; for 40 cycles.
qPCR primers are listed in Table S4. A melt curve was performed to
indicate there was not off-target amplification. Data was analyzed as
described by Hellemans et al. (2007) using the geometric mean of ACTB,
GAPDH, and RPL0 as an internal control. The All sgRNA sample
represents data from two independent transfection experiments. The data
for all remaining samples derives from technical replication using the
same RNA sample. P-values were calculated with paired sample t-tests on
the normalized levels of gene expression.
For mouse cells, total RNA was isolated from 5×103 FACS-sorted
cells using NucleoSpin RNA XS (Macherey-Nagel) and reverse
transcribed with the SuperScript VILO kit (Life Technologies). cDNA
input was standardized and real-time polymerase chain reaction (PCR)
was performed with TaqMan master Mix (Applied Biosystems), 18
s-rRNA probe (VIC-MGB; Applied Biosystems), and Cdkn1a gene
probe (FAM-MGB; Mm04205640_g1, Applied Biosystems) on a
StepOnePlus Real-Time PCR System (Life Technologies). Samples
were normalized to expression of 18S and fold change determined by
the ΔΔCt method.
Western blot
32D cells transduced with dCas9-D3A or dCas9-mD3A with or without
sgRNAs were grown in the presence of doxycycline for 12 days, collected
andwashedwith ice cold PBS twice. Cells were then lysed in complete RIPA
buffer containing protease inhibitors (Santa Cruz Biotechnology). 20 µg of
protein lysates were separated on 10% SDS-PAGE gels and transferred to
nitrocellulose membranes (Millipore). Membranes were subsequently
probed to detect fusion proteins using primary antibodies recognizing
Cas9 (Active Motif ) or β-actin (Santa Cruz) and detection was performed
using horseradish-peroxidase-conjugated secondary mouse antibody (Santa
Cruz) and chemiluminescence (Millipore).
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